Heart attack drug shows promise in lowering cholesterol and inflammation
NCT ID NCT04082442
First seen Oct 31, 2025 · Last updated Apr 30, 2026 · Updated 25 times
Summary
This study tested whether adding evolocumab, a drug that lowers bad cholesterol, to standard care helps people who recently had a heart attack. The goal was to see if it reduces cholesterol and inflammation in the heart and blood vessels. The study involved 100 adults aged 25 to 90 who had a specific type of heart attack.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE CORONARY SYNDROME are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
The Johns Hopkins Hospital
Baltimore, Maryland, 21287, United States
Conditions
Explore the condition pages connected to this study.